



Dedicated To Life

February 9, 2024

The Listing Department
BSE Limited
P J Towers, Dalal Street,
Mumbai-400001

Code: 532321

The Listing Department
National Stock Exchange of India Limited
Exchange Plaza, C/1, G Block,
Bandra-Kurla Complex, Bandra (East)
Mumbai – 400051

Code: Zyduslife

Dear Sir/ Madam,

Sub: Outcome of the board meeting of Zydus Lifesciences Limited (“Company”) held on February 09, 2024.

In continuation of our letter dated February 5, 2024 and in terms of Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (“**Listing Regulations**”), we wish to inform you that the board of directors of the Company (“**Board**”), at its meeting held today (i.e., February 9, 2024), has *inter-alia*, approved:

1. the buyback of not exceeding 59,70,149 (Fifty Nine Lakhs Seventy Thousand One Hundred Forty Nine) fully paid-up equity shares of the Company, each having a face value of INR 1/- (Indian Rupee one only) (“**Equity Shares**”), representing up to 0.59% of the total number of equity shares in the paid-up equity share capital of the Company, at a price of INR 1,005/- (Indian Rupees One Thousand Five only) per Equity Share (“**Buyback Price**”) payable in cash for an aggregate amount not exceeding INR 600,00,00,000/- (Indian Rupees Six Hundred Crores only) (“**Buyback Size**”) being 5.28% and 3.33% of the aggregate of the fully paid-up equity share capital and free reserves as per the latest audited standalone and consolidated financial statements of the Company as at March 31, 2023, respectively. The Buyback Size does not include transaction costs viz. brokerage costs, fees, turnover charges, applicable taxes such as buyback tax, securities transaction tax, goods and services tax, stamp duty, etc., expenses incurred or to be incurred for the buyback like filing fees payable to the Securities and Exchange Board of India (“**SEBI**”), advisors/ legal fees, public announcement publication expenses, printing and dispatch expenses and other incidental and related expenses, etc.

The buyback is proposed to be made from all of the equity shareholders / beneficial owners of the Company, including the promoters of the Company (as defined under SEBI

Zydus Lifesciences Limited (formerly known as Cadila Healthcare Limited)

Regd. Office : 'Zydus Corporate Park', Scheme No. 63, Survey No. 536, Khoraj (Gandhinagar), Nr. Vaishnodevi Circle, S. G. Highway, Ahmedabad-382 481, Gujarat, India. | Phone : +91-79-71800000, +91-79-48040000
website : www.zyduslife.com | CIN : L24230GJ1995PLC025878





Dedicated To Life

(Substantial Acquisition of Shares and Takeovers) Regulations, 2011), who hold Equity Shares as on the record date, on a proportionate basis through the “tender offer” route, in accordance with the provisions contained in the Securities and Exchange Board of India (Buy-Back of Securities) Regulations, 2018, as amended (“**Buyback Regulations**”) and the Companies Act, 2013, as amended and rules made thereunder;

2. February 23, 2024 as the record date for the purpose of determining the entitlement and the names of equity shareholders who would be eligible to participate in the buyback, in accordance with Regulation 42 of the Listing Regulations and Regulation 9(i) of the Buyback Regulations (“**Record Date**”); and
3. the formation of a buyback committee (“**Buyback Committee**”) and delegated its powers to the Buyback Committee to do all such acts, deeds, matters and things as it may, in its absolute discretion, deem necessary, expedient, usual or proper in connection with the Buyback.

The pre-buyback shareholding pattern as on February 2, 2024 is enclosed as **Annexure**. Please note that the details regarding the post-buyback shareholding pattern have not been provided since the actual number of Equity Shares that are bought back and category of shareholders from whom the Equity Shares will be bought back cannot be determined at this stage.

The public announcement setting out the process, timelines, and other requisite details will be released in due course in accordance with the Buyback Regulations.

We would like to inform you that the said meeting commenced at 11.05 a.m. and concluded at 12.45 p.m.

We request you to kindly take the above on record.

Thanking you,
Yours sincerely,

For, **Zydus Lifesciences Limited**

Dhaval Soni
Company Secretary & Compliance Officer

Encl. As above.



Annexure

Pre-buyback shareholding pattern of the Company as on February 2, 2024 is set out below:

Sr. No.	Shareholder Category	No. of shareholders	No. of Equity Shares	% shareholding
1.	Promoter and promoter group	8	75,89,40,186	74.98
2.	Mutual funds	159	7,07,65,957	6.99
3.	Alternative investment funds	12	7,08,524	0.07
4.	Foreign portfolio investor	292	5,25,99,153	5.20
5.	Financial institutions / banks	9	1,28,094	0.01
6.	Insurance companies	49	5,91,13,202	5.84
7.	Central/ State Governments	2	600	0.00
8.	Individuals	2,90,822	5,47,96,231	5.41
9.	NBFCs registered with RBI	6	14,005	0.00
10.	Investor Education Protection Fund	1	15,01,237	0.15
11.	Trusts	28	8,40,351	0.08
12.	HUF	3,694	15,35,558	0.15
13.	NRIs (repat and non-repat)	6,670	30,96,092	0.31
14.	Bodies corporate/ clearing members	908	61,36,947	0.61
15.	Unclaimed Suspense Account	1	2,22,430	0.02
16.	Others	83	18,05,572	0.18
	Total	3,02,744	101,22,04,139	100.00

Note: The post buyback shareholding pattern of the Company shall be ascertained subsequently.

